MedTrace Logo

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

NCT00220701 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-11-11

Study results available
· View outcomes & findings →

Summary

This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.

It is hypothesized that Escitalopram will be superior to placebo in improving depression, as well as psychosocial, temperamental, and cognitive functioning.

Conditions

  • Dysthymic Disorder

Interventions

DRUG

Lexapro (escitalopram)

antidepressant drug selective serotonin reuptake inhibitor (SSRI)

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • St. Luke's-Roosevelt Hospital Center

    lead OTHER

Principal Investigators

  • David J. Hellerstein, MD · St. Luke's-Roosevelt Hospital, and NY State Psychiatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2008-11-30
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220701 on ClinicalTrials.gov